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Background: High myeloperoxidase (MPO) levels and low levels of high-density lipoprotein cholesterol (HDL-C) are associated with adverse 
cardiovascular (CV) outcomes. The impact of combining MPO with measures of HDL quantity and quality is unknown.
Methods: 3 year incidence of major adverse cardiovascular events (MACE: death, myocardial infarction, stroke) was recorded in 4300 patients 
undergoing angiography. The relationship between levels of HDL-C, apoA-I and arylesterase and incidence of MACE, according to MPO were studied.
Results: Patients had median levels of HDL-C (33.5 mg/dL), apoA-I (116 mg/dL), MPO (110 pmol/L) and arylesterase (102 μmol/min/mL). More 
MACE was observed with increasing MPO and decreasing levels of HDL-C, apoA-I and arylesterase. High levels of HDL-C, apoA-I and arylesterase 
predicted cardioprotection at all MPO levels (p<0.05). Combining MPO with HDL-C, apoA-I or arylesterase resulted in the greatest discrimination 
of CV risk. Combining the low quartile of HDL-C, apoA-I or arylesterase with the high MPO quartile resulted in the highest MACE rate (20.1-20.8%) 
while the high quartile of HDL markers and low MPO quartile was associated with the lowest MACE rate (6.1-7.6%, p<0.03). Patients with low 
arylesterase/high MPO had a >10-fold greater rate of mortality than patients with high arylesterase/low MPO (15.2 v 1.3%, p<0.05).
Conclusion: Measures of HDL quantity and quality predict CV outcome at all MPO levels. Combining MPO and HDL markers improves CV risk 
prediction. 
3-Year Event Rate for Death, Myocardial Infarction or Stroke
MPO
Q1 Q2 Q3 Q4
Q1 HDL-C 11.5 12.6 19.9 20.1
Q4 HDL-C 7.2 11.6 14.8 13.5
Q1 ApoA-I 10.8 15.6 20.8 20.4
Q4 ApoA-I 7.6 10.0 12.1 17.4
Q1 Arylesterase 19.9 19.7 21.6 20.8
Q4 Arylesterase 6.1 6.7 9.7 9.4
